Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
Holdings in Q4 2025
Holdings as of Dec 31, 2025, filed Feb 17, 2026. Long positions only; changes compare share counts with Q3 2025.
- Positions
- 29
- −4 vs. Q3 2025
- Portfolio value
- $3.73B
- +$355.2M (+10.5%) vs. Q3 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NUVLNuvalent, Inc. | COM | 5,269,433 | $530.1M | 14.2% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 6,644,403 | $529.2M | 14.2% | +421,112+6.8% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 5,724,016 | $373.2M | 10.0% | +1,075,000+23.1% | Added | History |
| GMABGenmab A/S | SPONSORED ADS | 7,039,834 | $216.8M | 5.8% | +3,222,983+84.4% | Added | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 2,562,154 | $209.8M | 5.6% | −103,544−3.9% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,417,473 | $191.2M | 5.1% | −146,723−9.4% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 7,544,172 | $188.6M | 5.0% | +750,000+11.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 4,068,020 | $187.7M | 5.0% | +283,265+7.5% | Added | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 759,565 | $167.8M | 4.5% | −201,599−21.0% | Reduced | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 6,541,210 | $162.3M | 4.3% | +371,079+6.0% | Added | History |
| SRRKScholar Rock Holding Corp | COM | 3,062,157 | $134.9M | 3.6% | +1,052,412+52.4% | Added | History |
| URGNUroGen Pharma Ltd. | COM | 4,473,648 | $104.8M | 2.8% | +257,564+6.1% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 2,210,774 | $102.9M | 2.8% | −340,000−13.3% | Reduced | History |
| APGEApogee Therapeutics, Inc. | COM | 1,123,243 | $84.8M | 2.3% | −398,514−26.2% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 3,691,475 | $67.4M | 1.8% | +1,686,110+84.1% | Added | History |
| ERASErasca, Inc. | COM | 14,159,095 | $52.7M | 1.4% | +599,078+4.4% | Added | History |
| BBIOBridgeBio Pharma, Inc. | COM | 684,277 | $52.3M | 1.4% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 1,710,316 | $51.8M | 1.4% | +1,710,316 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,467,266 | $48.1M | 1.3% | 00.0% | Unchanged | History |
| LXEOLexeo Therapeutics, Inc. | COM | 4,763,198 | $47.3M | 1.3% | +4,763,198 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,443,102 | $44.9M | 1.2% | −1,166,251−44.7% | Reduced | History |
| OCULOcular Therapeutix, Inc | COM | 2,935,284 | $35.6M | 1.0% | −562,023−16.1% | Reduced | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 810,286 | $32.7M | 0.9% | +810,286 | New | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | COM NEW | 2,261,749 | $28.3M | 0.8% | +395,608+21.2% | Added | History |
| VORVor Biopharma Inc. | COM NEW | 1,750,000 | $22.9M | 0.6% | +1,750,000 | New | History |
| ASMBAssembly Biosciences, Inc. | COM NEW | 665,251 | $22.6M | 0.6% | +665,251 | New | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,401,217 | $19.6M | 0.5% | +2,401,217 | New | History |
| IVAInventiva S.A. | ADS | 4,000,000 | $18.6M | 0.5% | +4,000,000 | New | History |
| KLRSKalaris Therapeutics, Inc. | COM | 700,000 | $5.91M | 0.2% | +700,000 | New | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $182.9M | – |
Sold out since Q3 2025 (12)
Positions held at the end of Q3 2025 that are gone from this filing.
| Security | Class | Shares in Q3 2025 | Value in Q3 2025 | % of portfolio in Q3 2025 | History |
|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 4,373,770 | $411.8M | 12.2% | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 2,673,555 | $107.3M | 3.2% | History |
| JANXJanux Therapeutics, Inc. | COM | 2,920,258 | $71.4M | 2.1% | History |
| ALKSAlkermes plc. | SHS | 1,719,334 | $51.6M | 1.5% | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,073,461 | $50.0M | 1.5% | History |
| PHVSPharvaris N.V. | COM | 1,835,494 | $45.8M | 1.4% | History |
| COGTCogent Biosciences, Inc. | COM | 3,156,398 | $45.3M | 1.3% | History |
| TNGXTango Therapeutics, Inc. | COM | 3,086,184 | $25.9M | 0.8% | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 1,900,000 | $25.8M | 0.8% | History |
| DYNDyne Therapeutics, Inc. | COM | 1,898,950 | $24.0M | 0.7% | History |
| IRONDisc Medicine, Inc. | COM | 247,716 | $16.4M | 0.5% | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 372,869 | $10.4M | 0.3% | History |